Kausik Kumar Ray, MD, FACC
Professor
Imperial College London

Printed as of 11/17/2026

Disclosures

Personal Commercial (24)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Amgen	Consultant Fees/Honoraria	Modest (< $5,000)	*Prevention*
Amgen	Research/Research Grants ‡ *Da Vinci, FHSC*	Significant (>= $5,000)	
Astra Zeneca	Consultant Fees/Honoraria	Significant (>= $5,000)	*Prevention*
Boehringer Ingelheim	Consultant Fees/Honoraria	Modest (< $5,000)	*Prevention*
Cleerley	Consultant Fees/Honoraria	Modest (< $5,000)	*Prevention*
Daiichi Sankyo	Consultant Fees/Honoraria	Significant (>= $5,000)	*Prevention*
Daiichi Sankyo	Research/Research Grants ‡ *EAS FHSC*	Significant (>= $5,000)	*Prevention*
Eli Lilly and Company	Consultant Fees/Honoraria	Significant (>= $5,000)	*Prevention*
Esperion	Consultant Fees/Honoraria	Modest (< $5,000)	*Prevention*
Menarini	Consultant Fees/Honoraria	Modest (< $5,000)	*Prevention*
MSD	Consultant Fees/Honoraria	Modest (< $5,000)	*Prevention*
New Amsterdam Pharma	Stock	Significant (>= $5,000)	*Prevention*
New Amsterdam Pharma	Consultant Fees/Honoraria	Significant (>= $5,000)	*Prevention*
Nodthera	Consultant Fees/Honoraria	Modest (< $5,000)	*Prevention*
Novartis Corporation	Consultant Fees/Honoraria	Significant (>= $5,000)	*Prevention*
Novo Nordisk	Consultant Fees/Honoraria	Significant (>= $5,000)	*Prevention*
PEMI31	Stock	Modest (< $5,000)	*Prevention*
Pfizer	Consultant Fees/Honoraria	Modest (< $5,000)	
Regeneron	Research/Research Grants ‡ *TOGETHER observational study*	Significant (>= $5,000)	
Sanofi	Research/Research Grants ‡ *Investigator Initiated RCT of decision support tool to optimise clinical care*	Significant (>= $5,000)	*Prevention*
SCRIBE	Stock	Significant (>= $5,000)	*Prevention*
SCRIBE	Consultant Fees/Honoraria	Significant (>= $5,000)	*Prevention*
Silence Therapeutics	Consultant Fees/Honoraria	Significant (>= $5,000)	*Prevention*
Ultragenix	Research/Research Grants ‡ *PASS Registry*	Significant (>= $5,000)	*Prevention*

Additional Personal Commercial Disclosures for Education Activities (7)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Algorithm	Speaker's Bureau	Significant (>= $5,000)	*Prevention*
Amgen Inc.	Speaker's Bureau	Modest (< $5,000)	*Prevention*
AstraZeneca Pharmaceuticals	Speaker's Bureau	Significant (>= $5,000)	*Prevention*
Daiichi Sankyo	Speaker's Bureau	Significant (>= $5,000)	*Prevention*
Novartis Corporation	Speaker's Bureau	Significant (>= $5,000)	*Prevention*

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Organon	Speaker's Bureau	Modest (< $5,000)	Prevention
Torrent Pharmaceuticals	Speaker's Bureau	Modest (< $5,000)	Prevention

Personal Organizational or Other Non-Commercial (4)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Boehringer Ingelheim	Speaker's Bureau	Modest (< $5,000)	Prevention
Novo Nordisk	Speaker's Bureau	Modest (< $5,000)	Prevention
SANOFI	Speaker's Bureau	Modest (< $5,000)	Prevention
Viatris	Speaker's Bureau	Modest (< $5,000)	Prevention

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/1/2025
URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/1/2025
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 10/1/2025
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 10/1/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.